For decades, most industries, from petrochemicals to paper, have embraced continuous manufacturing processes. In contrast, the ultraconservative pharmaceutical industry has remained committed to batch operations. But recently, the demands of chemically complex and targeted drugs coming to market have caused many pharmaceutical companies to rethink the way they make medicines, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.